Viome Launches AI-Powered Full Body Intelligence™ Test To Help You Stay Healthy, Slow Aging, and Make Illness Optional
Built on unique RNA science and cutting-edge AI, Viome's at-home test redefines health by analyzing 100 million biomarkers to detect early signs of biological dysfunction linked to 25+ chronic health conditions.
BELLEVUE, Wash., April 14, 2025 /PRNewswire/ -- Viome Life Sciences, the leader in AI-powered, RNA-driven molecular diagnostics and precision nutrition, today launched its most transformative consumer product, redefining how individuals understand, track, and improve their health through evolving biological insights.
At the core of Viome's new experience is the radical idea that your genes are not your destiny, and your health outcomes are not static or predestined but measurable, modifiable, and within your control. Viome is the only company in the world that uses advanced RNA sequencing to decode your body's active gene expression and applies AI to translate that data into practical, daily health guidance. This includes what to eat, what to avoid, why you should eat certain foods, and how your personal health insights are connected to the most common diseases.
"Our medical industrial complex is reactive and waits until we experience symptoms or develop a disease instead of helping us stay healthy in the first place," said Naveen Jain, Founder and CEO of Viome. "Symptoms that we feel are the body's last cry for help. At Viome, we believe true prevention begins by listening to your body's earliest whispers long before illness takes hold. Our technology decodes your biological signals and translates these insights into daily, personalized nutrition and supplement guidance so you can take control of your health before symptoms arise."
Beyond DNA: A Test That Measures What's Actually Happening in Your Body Today
Viome's Full Body Intelligence™ Test is a simple at-home kit that uses RNA sequencing from stool (gut microbiome), saliva (oral microbiome), and a finger-prick blood (cellular function) sample to reveal how your current diet and lifestyle impact your body's systems.
Unlike static DNA tests that only show genetic potential or guess what might be happening in your body, Viome's RNA sequencing technology analyzes active human and microbial gene expression to detect early red flags like inflammation, microbial imbalance, and biological dysfunction before symptoms appear.
Powering this experience is Viome's proprietary AI engine, which is trained on the world's largest gene expression database. It analyzes over 100 quadrillion biological data points from over one million samples across 106 countries. The platform also integrates over 20,000 peer-reviewed scientific publications, continuously evolving to reflect the latest cutting-edge research. This dynamic foundation of data allows Viome to deliver clinically grounded and highly personalized food and precision supplement recommendations designed to help reverse risk and extend healthspan.
New Features included with Full Body Intelligence include:
Health ConnectionsA first-of-its-kind feature that connects Viome health scores to early biological indicators of 25+ chronic conditions, including autoimmune, cognitive, digestive, metabolic, and oral health concerns. These connections are grounded in independent peer-reviewed science, Viome's proprietary AI models, and real-time gene expression data — making Viome's Full Body Intelligence one of the most powerful tools for personalized, preventative health.
BioAge™ Score Measures millions of molecular data points to determine how fast your body is truly aging compared to your chronological age. This is driven by real-time molecular signals related to inflammation, metabolism, and cellular resilience, giving you a clear path to slow aging from the inside out.
InflammAging™ ScoreTracks how chronic, low-grade inflammation — one of the most insidious drivers of aging and chronic disease — impacts your resilience and longevity. This score gives you a window into how to proactively manage inflammation through targeted science-backed nutrition and lifestyle strategies to help you fight it at the source.
Personalized Boosters & Blockers™Viome's breakthrough approach to highlighting food-as-medicine - made personal, visible, and actionable. Every food, nutrient, and ingredient is tagged as a Booster (supports your biology and health goals) or Blocker (may fuel inflammation or imbalance). Each tag is personal and powered by real-time health scores. This level of functional insight turns your grocery list into a molecular strategy for prevention, where every bite is a targeted move toward optimal health.
"What sets Viome apart is that we don't just measure your biology, but we measure change over time," said Dr. Momo Vuyisich, Viome's Chief Science Officer. "RNA allows us to track your body in action and how it responds and evolves with your environment, exercise, lifestyle, nutrition, sleep, and stress level. Our recommendations continuously adapt based on the biological signals we detect, guiding you according to what your body needs right now which may be very different from what it needed six months ago. In a world where genetic data is static, Viome delivers the opposite: a living, dynamic reflection of your biology that empowers you to course correct your health before a disease takes hold."
A Consumer Product for a Health System That Doesn't Exist Yet
Viome's new Full Body Intelligence experience bridges a long-standing gap in consumer health by offering a product that's not just smart or personalized but clinically grounded and rooted in functional, preventative care.
"Health shouldn't be something you only think about when things go wrong," said Dr. Guru Banavar, Viome's Chief Technology Officer. "Just like you track your finances to build wealth, you should monitor your biology to stay ahead of your health. Your body is always changing, and your health plan needs to evolve with it. That's why we built an intelligent molecular feedback loop, giving you the power to take personalized action in real-time and invest in your health like you would your financial future."
Viome's latest insights are available now to all Full Body Intelligence™ users. Learn more at Viome.com.
About Viome
Viome Life Sciences is a health technology company pioneering AI-powered, RNA-driven molecular diagnostics and precision nutrition to transform how we prevent chronic symptoms and extend healthy living. Viome's proprietary RNA sequencing and AI platform analyzes gene expression from the human body and microbiome to create a dynamic view of biological health.
Viome's platform begins with the Full Body Intelligence Test, the most comprehensive at-home test available. By analyzing gene expression from stool, blood, and saliva, it reveals how diet and lifestyle impact key systems like the microbiome, immune function, inflammation, aging, and more.
Viome translates this data into personalized food recommendations, custom-formulated supplements, and health scores that track inflammation, aging, microbial balance, and glycemic response to empower users to act early and stay well.
Viome is also advancing clinical diagnostics, including the FDA Breakthrough Device-designated CancerDetect™ test for oral and throat cancer, and expanding into metabolic, digestive, and neurological disease detection.
With over one million biological samples analyzed and the world's largest gene expression database, Viome is redefining preventive care. The company is backed by Khosla Ventures, Bold Capital Partners, Marc Benioff, and WestRiver Group.
For more information:Viome Website: https://www.viome.com/Viome Research: https://www.viome.com/publicationsViome on LinkedIn: https://www.linkedin.com/company/viomelifesciences:
Media Contacts:
Helene VollbrachtChief Product Strategy Officer, Corporate Brand & Communicationshelene@viome.com
Chris HempelSpark Public Relationschris.hempel@sparkpr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/viome-launches-ai-powered-full-body-intelligence-test-to-help-you-stay-healthy-slow-aging-and-make-illness-optional-302427212.html
SOURCE Viome Life Sciences
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
8 hours ago
- Business Wire
From Seattle to Chiba: Okayama University Taps AGC Biologics' Global Pathway for New Therapeutic
SEATTLE & CHIBA, Japan--(BUSINESS WIRE)--AGC Biologics, your friendly CDMO expert, today announced a new service agreement with Okayama University, a prominent national university in Japan. This project will leverage AGC Biologics' global network, with the mammalian cell line development capabilities in Seattle, USA, and cGMP mammalian manufacturing facility in Chiba, Japan, working together to advance a new therapeutic program for the university. Under the agreement, AGC Biologics will perform cell line development with its proprietary CHEF1™ expression platform in Seattle. CHEF1's track record includes the production of more than 55 different molecules and the development of five commercial products brought to market. The program will then be transferred to the company's facility in Chiba for process development for clinical trials in 2026. The collaboration between its Asian and U.S. sites highlights AGC Biologics' ability to offer research institutions a seamless, global pathway from early-stage development to clinical manufacturing. 'This project is a perfect example of our winning global blend, combining the world-class cell line development excellence in Seattle with the most-advanced cGMP-compliant mammalian cell culture manufacturing capabilities available in Japan,' said Susumu Zen-in, General Manager of AGC Biologics' Chiba facility. 'By providing a high level of global standard expertise and an emphasis on flexibility, we're able to effectively serve prestigious academic institutions like Okayama University working to bring vital new medicines to patients.' Okayama University selected AGC Biologics for its integrated global network and its unique position in Japan. The Chiba facility offers mammalian cell culture-based services to serve the needs of customers from Japan and the surrounding regions. This partnership underscores AGC Biologics' commitment to supporting academic and research institutions by providing the technical creativity and specialized services needed to solve complex challenges and advance important new therapies. To learn more about AGC Biologics' global network of services, visit About AGC Biologics AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. We currently employ more than 2,600 Team Members worldwide. AGC Biologics is a part of AGC Inc.'s Life Science Business. The Life Science Business runs 10+ facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit
Yahoo
15 hours ago
- Yahoo
Arthrex NanoScope™ System Receives Pediatric Clearance for Orthopedic, Laparoscopic Procedures
NAPLES, Fla., July 16, 2025 /PRNewswire/ -- Arthrex, a global leader in minimally invasive surgical technology, announced that it has received U.S. Food and Drug Administration (FDA) clearance to use the Arthrex NanoScope™ operative arthroscopy system for pediatric orthopedics and laparoscopy. The NanoScope system is a compact, high-resolution mobile imaging platform featuring the industry's first high-definition, chip-on-tip camera — known as the NanoNeedle Scope — engineered specifically to meet the unique anatomical and procedural needs of pediatric patients. "This innovative and disruptive technology is transforming the way we approach diagnostic and least-invasive surgical treatments, and we are extremely proud to expand its indications to the field of pediatric orthopedics and laparoscopy," said Arthrex President and Founder Reinhold Schmieding. The NanoScope system can be used in common pediatric cases like general knee arthroscopy, meniscal treatments, anterior cruciate ligament (ACL) reconstruction, general shoulder arthroscopy and hernia or diagnostic laparoscopy in the abdomen. The smaller scope is designed to minimize the potential risk of damaging anatomical structures upon entry along with neurovascular structures. "FDA clearance for use of the NanoScope system in pediatric patients is an important, exciting step forward," said J. Lee Pace, MD. "Its smaller size makes it ideal for navigating pediatric joints while still delivering excellent image quality for routine or even more complex cases." Most Nano arthroscopy procedures can be performed outside of a traditional operating room, such as in a physician's office or an ambulatory surgery center, offering a more convenient and flexible option for both diagnosis and treatment. Patients and doctors can also discuss anesthesia options to determine the level that best fits a particular procedure and the patient's comfort level, from local anesthesia — allowing the patient to stay awake during treatment — to twilight anesthesia, or mild sedation. This minimally invasive approach also means a smaller scar,1 less risk of infection2 and the potential for less pain, reducing the need for prescriptive pain medications.3 To learn more about Nano arthroscopy, visit For more information, downloadable multimedia assets and interview requests for subject matter experts, contact Arthrex Media Relations at media@ About Arthrex Arthrex, headquartered in Naples, Florida, is a global medical device company and leader in multispecialty minimally invasive surgical technology innovation, scientific research, manufacturing and medical education. The company has pioneered the field of arthroscopy and sports medicine and develops more than 1,000 new products and related procedures annually to advance minimally invasive orthopedic surgery, trauma, spine, cardiothoracic, orthobiologics and arthroplasty innovation worldwide. Arthrex also specializes in the latest 4K multispecialty surgical visualization and OR integration technology solutions. For more information, visit Physician is a paid consultant of Arthrex, Inc. References Schaver AL, Lash JG, MacAskill ML, et al. Partial meniscectomy using needle arthroscopy associated with significantly less pain and improved patient reported outcomes at two weeks after surgery: a comparison to standard knee arthroscopy. J Orthop. 2023;41:63-66. doi:10.1016/ McMillan S, Chhabra A, Hassebrock JD, Ford E, Amin NH. Risks and complications associated with intra-articular arthroscopy of the knee and shoulder in an office setting. Orthop J Sports Med. 2019;7(9):2325967119869846. doi:10.1177/2325967119869846 Bradsell H, Lencioni A, Shinsako K, Frank RM. In-office diagnostic needle arthroscopy using the NanoScope™ arthroscopy system. Arthrosc Tech. 2022;11(11):e1923-e1927. doi:10.1016/ View original content to download multimedia: SOURCE Arthrex, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
15 hours ago
- Business Wire
Nanochon Announces Health Canada Approval for First in Human Investigation
WASHINGTON--(BUSINESS WIRE)--Nanochon, a Washington, DC and Baltimore, MD-based orthopedic device biotech company developing an implant for treating articular cartilage defects in the knee, is thrilled to announce that it was granted Health Canada Approval for their first in human clinical trial. The trial will be led by Principal Investigator, Dr. Fathi Abuzgaya, who will collaborate with Sports Medicine Specialists, Drs. Joel Lobo, Kajeandra Ravichandiran and Marcin Kowalczuk as Sub-Investigators, at the Durham Bone & Joint Specialists (DBJS), located in Ontario, Canada. Dr. Fathi Abuzgaya is an orthopedic surgeon by training and an esteemed researcher with a track record over the last 25 years, leading +600 clinical trials in all phases and therapeutic areas. 'Our team is delighted that we are the first center to start enrolling participants for the Chondrograft™ study, which represents a novel, minimally invasive treatment for patients with loss of or damaged knee cartilage,' Dr. Abuzgaya commented. 'DBJS is a multidisciplinary musculoskeletal center providing non-operative and operative treatments with accessibility to a variety of sub-specialties. Our study site with dedicated researchers enables greater, more efficient patient recruitment for clinical research and we are privileged to support Nanochon.' The Nanochon Chondrograft™ System is being evaluated in a prospective, 10 patient, early feasibility study for use in knee cartilage restoration in eligible patients between 22 and 60 years of age having femoral condyle and /or trochlea articular cartilage lesions who have failed conservative therapy, in addition to meeting other criteria. The study is designed to assess the safety and performance of Chondrograft™, and procedural goals include regrowth of the cartilage-bone matrix, improvement in knee function and pain, and delayed need for arthroplasty. 'Achieving Health Canada approval allows us to gain the clinical data needed to take a giant step forward towards design and execution of a large pivotal North American study,' said Ben Holmes, CEO of Nanochon. 'We have the utmost confidence in Dr. Abuzgaya and his clinical team at DBJS to help us recruit the right patients and execute the trial protocol that we have so carefully designed.' While the first in human trial will take place in Canada, this represents just the first step towards a larger clinical program. 'Thousands of patients with chondral defects, that may evolve to osteoarthritis, live with a reduced quality of life. We are looking forward to the potential for a new treatment option and are excited to begin the Chondrograft™ study at DBJS,' states Dr. Joel Lobo. 'The results of this study could open up a new surgical option, that is minimally invasive to address this unmet clinical need.' Throughout the clinical trial design and regulatory approval process, Nanochon was supported by HN Clinical Consulting (Missouri). "Improving the lives of young adults and athletes by providing a solution to restore knee cartilage and hopefully help patients avoid costly knee replacement is a crucial therapy needed in the orthopedic world," said Heather Neill, Founder and Principal. "We appreciate Health Canada's thought-provoking questions throughout their review that helped us put forward the strongest application possible, which ultimately led to our approval.' HN Clinical Consulting will continue to support the full life cycle of Chondrograft™. About HN Clinical Consulting HN Clinical Consulting, LLC, brings a strategic focus to each project, keeping the goal of commercialization in sight. Building strong relationships with all stakeholders and maintaining a clinical strategic goal of project-oriented success to support long term Sponsor strategy/exit is key to development of clinical programs. The objective set is to stay ahead by planning for podium presence, publication, and reimbursement while designing the Clinical Investigational Plan. About Nanochon Nanochon is a biotech and medical device company focused on developing innovative orthopedic solutions. Chondrograft™ is a minimally-invasive 3D printed implant that has allowed for immediate weight-bearing and motion in pre-clinical studies. The implant is based on research from the Tissue Engineering and Nanotechnology lab at the George Washington University, and is designed to integrate with healthy tissue over time, for maximum stability and benefit to the patient. Nanochon has the potential to deliver more successful and longer-lasting recovery for patients than current standard of care. Our mission is to develop a new approach to treat cartilage defects so that the hundreds of thousands of young, active patients with joint damage can return to their lifestyles without undergoing costly and invasive short-term fixes.
